Vasella touts Novartis' diversification


Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, saying that it's well on its way to returning to dynamic growth.

Vasella acknowledged that the pharma biz remains difficult, but he praised Novartis' pipeline and cited the new Alcon deal as evidence that the company will be strengthening itself through diversification. Last week, Novartis agreed to buy 25 percent of the eye care company for $11 billion and another big chunk by 2010 for $28 billion, giving it 72 percent controlling interest in the U.S.-based Alcon.

Meanwhile, Alcon announced that it's planning to build a manufacturing facility in Singapore as a beachhead for Asian distribution of its pharmaceutical products. The company plans to break ground in 2009 and have the plant fully operational by 2012.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

ALSO: A new study shows that Novartis' Reclast/Aclasta bone drug outperformed Sanofi-Aventis' Actonel at increasing bone mass in patients whose osteoporosis was caused by steroids. Release | Report

Related Articles:
Novartis taps new U.S. pharma chief. Novartis report
Novartis discovery chief departs in shakeup. Novartis report
CEO: Novartis plans big restructuring. Novartis report
Novartis pledges $39B for Alcon. Novartis report
Cash-rich Novartis CEO mulls biotech buyouts. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.